The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.
Daniel Virgil Thomas Catenacci
Honoraria - Genentech
Nathan Bahary
No relevant relationships to disclose
Martin J. Edelman
No relevant relationships to disclose
Sreenivasa R. Nattam
No relevant relationships to disclose
Robert de Wilton Marsh
No relevant relationships to disclose
Andreas Kaubisch
No relevant relationships to disclose
James Alfred Wallace
No relevant relationships to disclose
Deirdre Jill Cohen
No relevant relationships to disclose
Patrick J. Stiff
No relevant relationships to disclose
Bethany G. Sleckman
No relevant relationships to disclose
Sachdev P. Thomas
No relevant relationships to disclose
Heinz-Josef Lenz
Honoraria - Genentech
Research Funding - Genentech
Les Henderson
No relevant relationships to disclose
Ciara Zagaya
No relevant relationships to disclose
Michael Vannier
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Walter Michael Stadler
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech
Hedy Lee Kindler
No relevant relationships to disclose